Press releases
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
More ▼
Key statistics
On Friday, GlycoMimetics Inc (GKO:DUS) closed at 0.239, 7.90% above its 52-week low of 0.2215, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2445 |
---|---|
High | 0.2475 |
Low | 0.233 |
Bid | 0.236 |
Offer | 0.2525 |
Previous close | 0.243 |
Average volume | 2.00k |
---|---|
Shares outstanding | 64.46m |
Free float | 62.48m |
P/E (TTM) | -- |
Market cap | 16.95m USD |
EPS (TTM) | -0.5791 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:31 BST.
More ▼